CClinicalTrials.gg
CompletedNCT05260866MENTALPEDUpdated Feb 23, 2023

Impact of the COVID-19 Pandemic on Mental Health Service Utilization in Children and Adolescents

An observational study in Mental Disorder, Child, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-02-23.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500,000
Ages
6 Years to 18 Years
Sex
All
01

Study summary

Mental health consequences of the COVID-19 pandemic may be vast and may potentially overwhelm the mental health system in a long-lasting manner. Evaluating the effects of the COVID-19 pandemic on mental health in vulnerable groups such as children and adolescents has become an immediate priority. The aim of this study is to evaluate the impact of COVID-19 pandemic on use of mental health resources namely 1) prescriptions of psychotropic medications and 2) mental health-related outpatient visits, hospitalizations and emergency department visits in children and adolescents in France. Secondary aim is to evaluate the impact of the pandemic on episodes of fatal and non-fatal self-harm episodes in the same population. This will be a population-based cohort study using data from healthcare claims, administrative medical and outpatient drug dispensation databases in France between January 1, 2016 and June 1, 2021. Findings will inform on the risk of upcoming outbreaks of mental disorders that can result in significant morbidity and mortality and guide timely targeted actions to improve mental health outcomes and wellbeing in the youngest.

Read the detailed description

Mental health consequences of the COVID-19 pandemic may be vast and may potentially overwhelm the mental health system in a long-lasting manner. Evaluating the effects of the COVID-19 pandemic on mental health in vulnerable groups such as children and adolescents has become an immediate priority. The aim of this study is to evaluate the impact of COVID-19 pandemic on use of mental health resources namely 1) prescriptions of psychotropic medications and 2) mental health-related outpatient visits, hospitalizations and emergency department visits in children and adolescents in France. Secondary aim is to evaluate the impact of the pandemic on episodes of fatal and non-fatal self-harm episodes in the same population. This will be a population-based cohort study using data from healthcare claims, administrative medical and outpatient drug dispensation databases in France between January 1, 2016 and June 1, 2021. Findings will inform on the risk of upcoming outbreaks of mental disorders that can result in significant morbidity and mortality and guide timely targeted actions to improve mental health outcomes and wellbeing in the youngest.

02

Conditions studied

  • Mental Disorder, Child

Keywords

  • pediatrics
  • COVID 19 pandemic
  • mental health
  • psychotropic drug
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 500,000 is above the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children and adolescents aged from 6 to 18 years

Inclusion criteria

  • Children and adolescents aged from 6 to 18 years
  • One dispensation of psychotropic medication or
  • One mental-health related hospitalization or
  • One reimbursement for an outpatient mental-health related consultation or
  • One eligibility to long-term diseases corresponding to long term psychiatric diseases or
  • One mental-health related cause of death using ICD-10 codes

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500,000 participants (actual)
Patient registry
No

Interventions

  • Othernational population-based study

    No intervention

06

What researchers measure

Primary outcomes

  1. To evaluate the impact of COVID-19 pandemic on use of mental health resources

    prescriptions of psychotropic medications; mental health-related outpatient visits; mental health-related hospitalizations and emergency department visits

    Time frame: 1 year

Secondary outcomes

  1. To evaluate the impact of COVID-19 pandemic on episodes of fatal and non-fatal self-harm episodes in children and adolescents in France

    monthly counts and rates of fatal and non-fatal self-harm episodes will be assessed throughout the study period

    Time frame: 1 year

07

Study locations

1 site
  • Robert Debre Hospital - Assistance Publique Hopitaux de Paris
    Paris, 75019, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05260866
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Agence Nationale de Recherche (ANR) National Research Agency
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Jul 1, 2021
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Last update
Feb 23, 2023

Study contacts

Florentia Kaguelidou, MD, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion